Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Kasra KasraianChief Technical Officer | PepGenPEPG | Open-market sale | 05/21 | 05/26 | 1,233 sh | $1.41 | $1,738.53 | −2.4% |
PepGenPEPG | Open-market sale | 03/04 | 03/06 | 1,879 sh2 trades | $6.23avg. | $11,708.99 | −2.4% | |
PepGenPEPG | Open-market sale | 03/04 | 03/06 | 5,275 sh2 trades | $6.23avg. | $32,876.35 | −1.7% | |
PepGenPEPG | Open-market sale | 03/04 | 03/06 | 2,084 sh2 trades | $6.23avg. | $12,988.52 | −1.8% | |
PepGenPEPG | Open-market buy | 25/09/30 | 25/10/01 | 200,000 sh | $3.20 | $640,000 | +4.2% | |
RA Capital Healthcare FundDirector | PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
Ra Capital ManagementDirector | PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
Peter KolchinskyDirector | PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
Rajeev M. ShahDirector | PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
RA Capital Nexus Fund IIDirector | PepGenPEPG | Open-market buy | 25/09/26 | 25/09/30 | 9,375,000 sh | $3.20 | $30,000,000 | +102.1% |
Paul StreckEVP, Head of R&D | PepGenPEPG | Open-market buy | 25/05/30 | 25/06/02 | 8,375 sh | $1.24 | $10,385 | +43.1% |
James G. McArthurPresident and CEO | PepGenPEPG | Open-market buy | 25/04/17 | 25/04/22 | 10,000 sh | $1.36 | $13,600 | +9.6% |
James G. McArthurPresident and CEO | PepGenPEPG | Open-market buy | 25/04/08 | 25/04/09 | 41,500 sh | $1.15 | $47,725 | +66.5% |
Mary Beth DeLenaGeneral Counsel | PepGenPEPG | Open-market sale | 25/02/26 | 25/02/26 | 1,432 sh | $1.68 | $2,405.76 | −47.7% |
PepGenPEPG | Open-market sale | 25/02/26 | 25/02/26 | 1,527 sh | $1.68 | $2,565.36 | −47.7% | |
PepGenPEPG | Open-market sale10b5-1 plan | 24/07/24–24/07/25 | 24/07/26 | 7,772 sh2 trades | $18.06avg. | $140,352.27 | −100.0% | |
Michelle L. MellionChief Medical Officer | PepGenPEPG | Open-market sale10b5-1 plan | 24/07/18 | 24/07/19 | 12,625 sh | $18.20 | $229,775 | −100.0% |
PepGenPEPG | Open-market sale10b5-1 plan | 24/07/12–24/07/16 | 24/07/16 | 9,189 sh2 trades | $18.01avg. | $165,533.52 | −100.0% | |
PepGenPEPG | Open-market sale10b5-1 plan | 24/07/01–24/07/02 | 24/07/03 | 912 sh2 trades | $18.01avg. | $16,427.34 | −100.0% | |
Michelle L. MellionChief Medical Officer | PepGenPEPG | Open-market sale10b5-1 plan | 24/06/24 | 24/06/26 | 9,260 sh | $18.19 | $168,439.4 | −100.0% |
